MedPeer
MedPeer runs a licensed-doctor community platform and pharma marketing services in Japan.
On the record
Checkpoint: MBO/going-private resolution and FY2026 full-year earnings disclosure
The call
MedPeer holds a smaller, verified doctor network against a bigger rival with equal reach and earlier AI moves, while its own profits shrink and ownership stays unresolved.
MedPeer runs a private social network where Japanese doctors share medical advice and knowledge, plus a business that sells this data to pharmaceutical companies. The company's main problem is that M3, a much larger competitor with over 330,000 doctors, already does the same things better and has no reason not to copy MedPeer's newer features. MedPeer's profits fell 76% recently, and the company announced a deal to go private in May 2025 but the stock still trades as of July 2026, leaving its ownership and value unclear. The biggest shift that could help MedPeer would be if the going-private deal closes and new owners invest heavily, but M3 has already started building its own AI tools for doctors, which means MedPeer's new artificial-intelligence product for reading medical research may not give it an advantage for long.
Why
01
AI pressure: Generic large language models (ChatGPT-style tools) doing literature summarization. LLMs can already summarize medical literature directly for doctors, competing with MedPeer's ClinPeer curation service. Could AI do the core job? Only partly.
02
Bigger players: M3, Inc.. M3 already has 330,000+ physicians versus MedPeer's 170,000, plus matching pharma ties, and shipped its own GenAI clinical tools in early 2025. Could a giant copy it? Yes, easily.
03
What protects it. A verified, licensed physician network built over 20 years, tied into pharma B2B contracts that reward trust over raw AI output.
What would change this call
MedPeer's MBO/going-private process reaches a final resolution or is formally abandoned. Shows whether ownership and strategic control get resolved or stay stalled.
MedPeer's FY2026 earnings show ordinary profit growth versus the FY2025 declines. Indicates whether the profit slide (down 32% and 76.8% YoY) has reversed.
M3 launches or expands GenAI clinical-literature tools competing directly with ClinPeer. Shows whether M3 is closing MedPeer's specialty-wedge advantage with its own scale.
MedPeer's FY2026 earnings show ordinary profit growth versus the FY2025 declines. Indicates whether the profit slide (down 32% and 76.8% YoY) has reversed.
M3 launches or expands GenAI clinical-literature tools competing directly with ClinPeer. Shows whether M3 is closing MedPeer's specialty-wedge advantage with its own scale.
Key numbers
- 170,000-180,000 registered physician members
- M3 has 330,000+ physicians, >90% Japan penetration
- Q3 FY2025 ordinary profit down 32.0% YoY to ¥700M
Named risks
- MBO announced May 2025 remains unresolved, stock still trading TSE Prime as of July 2026, leaving ownership ambiguous.
- Ordinary profit fell 32% YoY through Q3 FY2025, with one quarter down 76.8%, indicating active margin collapse.
- Growth product ClinPeer's core paper-curation function overlaps with generic LLM summarization capability.
- Dominant incumbent M3 operates an equivalent, larger physician platform with equal or greater AI investment.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| M3, Inc. | losing to | 170k-180k MedPeer members vs M3's 330,000+ physicians, over 90% penetration, as of May 2026 |
| M3, Inc. | losing to | M3 reportedly shipped generative-AI clinical-trial documentation tools in early 2025 |
| CareNet | contesting | Competes on medical video content and e-detailing for pharma marketing, per 2026 analyst source |
| Medley, Inc. | contesting | Telemedicine and EMR overlap noted in 2026 competitive analysis |
Questions people ask
- Is MedPeer in financial trouble?
- Not in acute trouble, but the numbers are softening: FY2024 revenue was 14.95 billion yen, up 2.81% year over year, with net income up about 140% (as of 2024-09-30). By Q3 FY2025 that momentum reversed, with recurring profit down 77% year over year (2025-06-30), and delisting has removed the public reporting investors could otherwise use to verify the trend.
- Who are MedPeer's biggest competitors?
- M3, Inc. is the dominant rival, running the same forum-and-survey model but reaching about 330,000 Japanese physicians, near 90% of the country's doctors, versus MedPeer's roughly 180,000 as of 2025-06-30. CareNet also competes directly in physician video and e-detailing services within Japan.
- Is MedPeer at risk from AI?
- The AI threat is rated 'building' rather than active: tools like OpenEvidence in the US and Xunfei Spark Medical in China are gaining adoption for physician-facing clinical queries elsewhere. If Japanese doctors start turning to AI tools instead of MedPeer's forums, the company's ad and survey traffic could thin, but this is a watch-item, not a confirmed hit as of the July 2026 assessment.
- What is MedPeer's biggest risk?
- The clearest risk is competitive scale: M3 already operates the identical physician-network model, reaching about 330,000 physicians (near 90% of Japan's doctors) versus MedPeer's roughly 180,000 as of 2025-06-30. MedPeer's main protection is its established base of paying pharma clients and a working physician network, but there is little structurally preventing rivals like M3 or CareNet from copying the approach.
- Does MedPeer have a strong competitive moat?
- No, its moat is comparatively weak. Its main protection is an established, paying base of pharma clients and a working physician network, but rivals such as M3, Inc. (reaching about 330,000 physicians, near 90% of Japan's doctors) and CareNet compete directly in the same physician video and e-detailing space, and there is little stopping new entrants from copying MedPeer's forum-and-survey model.
- What should I watch for with MedPeer going forward?
- Two dated items are worth tracking: whether MedPeer's recurring profit margin climbs back above 5% in FY2026 reporting, and whether M3 makes a direct price or share push against MedPeer by the end of 2026. A planned corporate rebrand under new private equity ownership, described as a 'second founding,' is also slated for February 2026 and worth checking against actual performance once it happens.
Timeline
- 2026-06-25Company-wide Claude Enterprise AI rollout completed for about 130 staff
- 2026-05-27ClinPeer expanded to pharmacists and nurses beyond physicians
- 2026-02-19Corporate rebrand launched marking self-described 'second founding period'
- 2025-09-03ClinPeer added case-discussion (symptom review) feature
- 2025-05-19MBO announced with Integral Corporation, tender offer reported at Y700-835 per share
- 2025-01-01ClinPeer full app released for oncology specialists
- 2024-10-28ClinPeer beta paper-curation feature launched for oncologists
- 2024-05-17FY2024 H1 results disclosed; mid-term FY2027 targets of Y20.7B revenue announced
- 2023-09-30FY2023 consolidated revenue reported at Y14.54 billion, up from Y8.45 billion
Revision history
30 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- MedPeerの医師の疑問解決サービス (2016-02-10)
- m3.com: Japan's Physician Network, CRM & WebMD Explained (2026-05-03)
- メドピア株式会社のWebマーケティングの採用 (2024-08-01)
- メドピアの損益計算書（2023年9月期）
- メドピア、上半期の売上高と利益は期初計画を超過 (2024-05-17)
- メドピア株式会社（6095）最新株価・配当情報
- MedPeer,Inc. (6095.T) Company Profile & Facts
- メドピア開発者ブログ, Claude Enterprise全社導入 (2026-06-25)
- がん専門医のための論文キュレーションアプリ「ClinPeer」を2025年1月にリリース (2024-10-28)
- ClinPeer「症例検討」提供開始 press release (2025-09-03)
- メドピア株式会社 (2026-05-27)
- 【注目株】メドピアMBO、700円は安すぎる？ (2025-05-19)